Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) ...

PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the Company will ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Sagimet Biosciences (SGMT) announced that three poster presentations featuring additional analyses from the Phase 2b FASCINATE-2 study of ...

This trial aimed to identify the antifibrotic effect and safety of hydronidone for CHB patients with significant liver fibrosis. It is anticipated that the findings of this study will further ...

Cardiac fibroblasts (CF) can become activated and produce excessive extracellular matrix, contributing to fibrotic remodeling ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs specifically designed to treat ...